Methods: Breast-CSCs expressing CD24 -/CD44 + surface markers were isolated from MDA-MB-231 cells by magnetic-assisted cell sorting method and validated using flow cytometry. A panel of forty extracts from barks and leaves of Doona nervosa, Garcinia quaesita, Garcinia zeylanica, Memecylon rostratum and Schumacheria castaneifolia were obtained by sequential solvent extraction and tested on bCSC-mammospheres derived from MDA-MB-231 and MCF-7 cells and normal mammary epithelial (MCF-10A) cells. Proliferation and cell stemness were analyzed using WST-1 cell proliferation assay and alkaline phosphatase assay. Results: Hexane and chloroform extracts of G. zeylanica and G. quaesita barks showed dosedependent reduction in proliferation and stemness in both bCSCs tested with less effect on MCF-10A cells. Hexane, chloroform and ethyl acetate extracts of S. castaneifolia bark selectively inhibited mammospheres of triple negative bCSCs cells. Conclusion: This study demonstrates that the non-polar extracts of G. zeylanica and G. quaesita, S. castaneifolia barks inhibit the proliferation of bCSCs of triple negative and estrogen-progesterone positive breast cancers. Findings of the present study may useful for developing a future anti-cancer therapeutics which can target bCSCs. This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest
INTRODUCTION
Cancer stem cells (CSCs) are a small fraction of cells that exists among functionally heterogeneous cell population of a tumour. CSCs also contain progenitor/stem cell like properties [1, 2] . They are responsible for tumour initiation, progression and contribute to the clonal expansion of terminally differentiated and fast cycling neoplastic cells [2] . CSCs undergo asymmetric cell division to self-renew and maintain their un-differentiated population [3] .
Conventional cancer therapies such as chemotherapy and radiotherapy reduce the size of tumours by killing the differentiated phenotypes but leave the CSCs untouched [4, 5] . This would proportionately increase the active CSCs in a tumour to form aggressive neoplasia. Therefore CSCs-targeted therapy should be a main part of all cancer therapies.
High overall mortality rate among breast cancer patients may be mainly due to the presence of therapy resistant types of breast cancers [6] . Triple negative breast cancer (TNBC) do not have molecular markers for estrogen receptor (ER-), progesterone receptor (PR-) and tyrosine kinase human epidermal growth factor-2 receptor (HER2-). Therefore TNBC is an aggressive variant, with a poorer short-term prognosis and has no available targeted therapies [7, 8] .
Natural compounds and natural product pharmacophores are already in use for anticancer therapies and well known for their curative powers and unexplainable benefits in treating cancers with lesser unpleasant toxicity and organ damages compared to synthetic drugs and radiation [9] . Drugs or lead molecules derived from plants could have unique chemical moieties to modulate vital signaling pathways involved in the maintenance of CSCs [10] . Such compounds have been investigated for their efficacy to block survival, proliferation and selfrenewable pathways of CSCs in several studies conducted by other authors [11] .
Sri Lanka is one of the focused hot spots for its biodiversity in tropical rainforests where endemic terrestrial evergreen plant is recorded to be approximately 70 % [12] . However the potential use of Sri Lankan endemic plants in eliminating bCSCs has not been experimentally investigated. Therefore in the present study we have tested five Sri Lankan endemic plants for their anticancer stem cell activities on bCSCs expressing CD24 -/CD44 + surface markers isolated from MDA-MB-231; a TNBC cell line and MCF-7; luminal -A subtype breast cancer cell line in vitro.
EXPERIMENTAL

Chemicals and reagents
Enriched bCSCs of MCF-7 cell line and cancer stem premium medium were purchased from ProMab Biotechnologies, Inc CA, USA. Dulbecco's modified Eagle's medium (DMEM), Lglutamine, trypsin-EDTA (ethylenediaminetetraacetic acid), Accutase ® solution, paraformaldehyde and Triton X-100 were purchased from Sigma-Aldrich, USA. Leibovitz's medium (L-15), fetal bovine serum (FBS), human recombinant insulin, penicillin-streptomycinamphotericin (PSA) and DMSO were purchased from American Type Culture Collection (ATCC), Manassas, USA. MEGM medium, epidermal growth factor (rhEGF), bovine pituitary extract (BPE), hydrocortisone, insulin, gentamicin sulfate, amphoterician-B (GA-100) were purchased from Lonza, Walkersville, MD, USA. WST-1 and alkaline phosphatase assay kits, primary and secondary antibodies were purchased from Abcam, Cambridge, MA, USA. Micro-beads conjugated to mouse monoclonal antibodies, bovine reagents and buffers for CSC isolation were obtained from Miltenyi Biotech GmbH-Germany. Organic solvents were obtained from Dae-Jung Chemical & Metal Co., Ltd, Korea.
Plant materials
All plants used in the present study were selected based on the previous scientific and traditional knowledge related to their anti-cancer properties [13] . The plant materials were collected from different locations of the wet zone region of Sri Lanka in April 2015. Leaves and barks of Doona nervosa Thwaites (Family -Dipterocarpaceae), Garcinia quaesita Pierre, Garcinia zeylanica Roxb. (Family -Clusiaceae), Memecylon rostratum Thwaites. (Family -Melastomataceae), and Schumacheria castaneifolia Vahl (Family -Dilleniaceae) were separately collected. All plant specimens were authenticated by the Botanist, N P T Gunawardena at the National Herbarium, Department of National Botanic Gardens, Royal Botanic Gardens, Peradeniya, Sri Lanka and deposited as herbarium specimens (no. 6/01/H/03 -1,2,3,4 and 5).
Preparation of plant extracts
Dried materials were pulverized to fine powder and 5 g from each plant bark and leaves were exhaustively extracted with four different solvents namely hexane, chloroform, ethyl acetate and methanol. The sequential extraction process was augmented by ultra-sonication while maintaining the temperature within 25 -40 °C. Residual solvents were evaporated from yielded extracts under reduced pressure and stored at -20 °C until use. Stock solution of each extract was prepared by dissolving the dried extracts with 100 % dimethyl sulfoxide (DMSO) and sterilized by passing through 0.22 µm membrane filters.
Cell culture
Human breast metastatic cancer cell line, MDA-MB-231 (triple negative) was cultured and maintained as monolayer culture in L-15 medium supplemented with 10 % (v/v) heat inactivated FBS, 10 µg/mL human recombinant insulin, 1 % PSA, 2 mM L-glutamine at 37 °C without CO 2 . MCF-10A (normal mammary epithelial) cell line was cultured in total MEGM growth medium at 37 °C in humidified 5 % CO 2 atmosphere.
Isolation of bCSCs from MDA-MB-231 cell line by MACS
MDA-MB-231 cells were harvested using 0.25 % (v/v) trypsin in 0.61 % (w/v) EDTA solution and washed with phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 and 2 mM KH 2 PO 4 , pH 7.4) to isolate CD24 -/CD44 + bCSCs like cells using magnetic assisted cell sorting technique (MACS). Briefly, the cell suspension was centrifuged at 300 g for 10 min and re-suspended in autoMACS™ running buffer (0.5 % BSA and 2 mM EDTA in PBS, pH 7.2). Then, 10 µL of human CD24 antibody conjugated with biotin was added into the cell suspension (1x10 7 cells/40 µL) and incubated at 2 -8 °C in the dark for 15 min.
After incubation, cell suspension was washed with running buffer and labelled with 20 µL of anti-biotin micro-beads at 2 -8 °C for 15 min in the dark. The cell suspension was centrifuged and the pellet obtained was re-suspended in fresh running buffer and eluted through MACS® LD (depletion) column to collect unlabeled cells (CD24 -) These cells were labeled with CD44 micro-beads (20 µL/1x10 7 cells in 80 µL running buffer) and incubated at 2 -8 °C in the dark for 15 min. Finally the cells were passed through MACS® LS (positive selection) column and cells bound to the magnetic beads were eluted with running buffer and then detached from the magnetic separator. The yielded CD24 -/CD44 + cell population was collected by centrifugation.
Mammosphere culture from isolated CD24 -/CD44 + cell population
The CD24 -/CD44 + cell population isolated from MDA-MB-231 cells and commercially available bCSCs of MCF-7 cells were suspended in serum-free cancer stem premium medium in ultra-low attachment 6-well plates for 7 -10 days to produce mammospheres. About 10 % of fresh media were used to replenish the culture every other day throughout the culture period. The tumorspheres were visualized under inverted phase contrast light microscope (Olympus CKX41SF, Olympus Co-operation, Tokyo, Japan). Prolonged mammosphere cultures were maintained to enrich bCSCs and sub-passaged by dissociating the mammospheres into single cells using 500 µL of 1X Accutase.
Validation of isolated bCSCs by flow cytometry
Ten days old mammospheres of bCSCs isolated from MDA-MB-231 cells were collected by centrifugation (800 g, 2 min), washed with PBS and dissociated using 1X Accutase. Collected cells were re-suspended in PBS and fixed with paraformaldehyde and permeabilised with 0.5 % Triton X-100.
Cells were incubated with rabbit polyclonal anti-CD44 primary antibody (Abcam, clone ab157107, at 1:100) for 30 min at 4 °C and then with APC conjugated goat anti-rabbit secondary antibody (Abcam, clone ab130805, at 1:200) for 30 min in the dark at 22 °C with gentle agitation. Similarly cells were incubated with anti-CD24 antibody (Abcam, clone ab76514, at 1:1000). Then cells were incubated with secondary antibody goat anti-mouse IgG H&L (Abcam, clone ab7064, 1:1000) conjugated with FITC fluorophore in same concentrations according to the manufacturer's instruction. In each step, cells were washed twice with ice-cold PBS and collected by centrifugation before analyzed using flow cytometry. Cells were acquired on a Partec Cyflow Cube 6 flow cytometer and analyzed with De Novo FCS Express software version 4.
Evaluation of anti-proliferative effects of plant extracts
Different concentrations (25, 50, 100, 200 and 400 µg/mL) of the forty crude extracts of bark and leaves of the five selected plants were tested for anti-proliferative effects on 4-days old bCSC mammospheres of MCF-7 and MDA-MB-231 cells, using WST-1 cell viability assay at 24 h post incubation as described by de la Mare et al [14] . Assay readings were recorded at 440 nm with reference at 650 nm using Synergy™ multimode microplate reader (BioTek, Winooski, USA). All experiments were carried out in quintuplicate.
Similarly, anti-proliferative effects of all plant extracts were tested on normal mammary epithelial (MCF-10A) cells (5 x 10 3 cells/well) using WST-1 assay at 24 h post treatment.
Alkaline phosphatase assay
Breast CSCs of MCF-7 and MDA-MB-231 cells were seeded at a density of 5x10 3 cells/well of 96-well ultralow attachment plate in 100 µL of cancer premium medium and allowed to form mammospheres. Mammospheres were treated on the 4 th day with selected active plant extracts and alkaline phosphatase activity assay was performed 24 h after treatment using ALP assay kit according to the manufacturer's protocol (Abcam, Cambridge, USA). Treated and untreated bCSC-mammospheres were washed with PBS and cellular alkaline phosphatase was extracted using extraction buffer. Cell suspensions were centrifuged for 3 min, at 13, 000 g and supernatants containing ALP enzyme were transferred into new vials. The supernatants were allowed to react with excess amount of 5 mM non-fluorescent 4methylumbelliferyl phosphate disodium salt (MUP) substrate for 1 h at room temperature, which yielded a fluorescent product, 4methylumbelliferone (4-MU) (Ex/Em = 360 nm/440 nm) in the presence of ALP. A calibration curve was drawn for standard concentrations of substrate versus ALP enzymes.
Statistical analysis
All data are presented as mean ± standard deviation (SD). Statistical significance and half maximal inhibitory concentration (IC 50 ) values were determined using GraphPad Prism software (San Diego, California). One-way analysis of variance (ANOVA) with Dunnett post-test was used to compare all treatment concentrations with control, and p < 0.05 was considered to indicate a statistically significant difference in ALP activity test.
RESULTS
Isolation of CD24 -/CD44 + cells and enrichment of bCSCs from MDA-MB-231 cell line
Isolated bCSCs from MDA-MB-231 cells by MACS method were grown on in vitro ultralow attachment culture flasks over a couple of weeks. As shown in Figure 1 During mammosphere development it were observed as shown in Figure 2 , the two different types of mammospheres are produced from bCSCs obtained from MDA-MB-231 and MCF-7 cell lines. They showed morphologically different sphere like masses. 
Anti-proliferative effects of plant extracts on bCSC-mammospheres
The extracts with IC 50 < 50 µg/mL were considered as active extracts. As indicated in Table 1 , a total of 10 (25 %) extracts showed potent anti-proliferative effects on bCSCs with IC 50 values less than 50 µg/mL.
Effects of plant extracts on stem cell marker alkaline phosphatase in bCSCs
Cellular ALP enzyme activity was measured by a sensitive fluorometric method in order to analyze the effects of most active plant extracts on the stemness of bCSCs grown as mammospheres at 24 h post treatment. All the active bark extracts tested in the present study remarkably reduced the ALP activity of both bCSC-mammospheres than their counterpart leaf extracts in general as indicated in Figure 3 and 
DISCUSSION
This study revealed that the bCSCs isolated from MDA-MB-231 cell line by MACS method using CD44 and CD24 antibodies consist significant amount of CD24 -/low CD44 +/high cell population (92.20 %). Zhang et al. have also isolated bCSCs from MDA-MB-231 and MCF-7 cell lines by MACS method using CD44, CD24 and CD326 antibodies and obtained CD24 -/CD44 + cell populations similar to the observations in the present study [15, 16] . Further, the flow cytometry results validated the efficacy of MACS method for the isolation of bCSCs in vitro. In the present study, mammospheres produced from estrogen receptor positive cells (MCF-7) showed clear Results are expressed as mean ± standard deviation of triplicate determinations; ***p < 0.001, **p = 0.001 to 0.01 and *p = 0.01 to 0.05 compared with control.
round, tightly cohesive structures displaying robust cell-cell adhesion under phase contrast microscopy as described by other authors [17] .
In the present study, the effect of forty plant extracts on cell proliferation and stemness of bCSCs was assessed by evaluating cell viability and alkaline phosphatase activity respectively. Effective elimination of chemotherapy and radiotherapy resistant CSC population is a requirement for any promising drug candidate that targets CSCs. Alkaline phosphatase (ALP), is used as a putative stem cell marker to characterize the pluripotency of CSCs [18] . 20] , there were no previous studies that have been carried out on the anti-proliferative effect of the above two plants on bCSCs. Besides, hexane extract of M. rostratum bark and chloroform extract of D. nervosa bark also reduced cell proliferation of bCSCs of MCF-7 and MDA-MB-231 cells respectively (with IC 50 : 34.77 and 24.48 µg/mL, respectively) while leaving no effect on MCF-10A cells.
The Sri Lankan endemic plants used in the present study have not yet been studied for their anti-proliferative properties on breast CSCs. However, in the present study we have tested anti proliferative effects of these plants extracts at a single incubation time interval since the main aim of this study is to screen selected plant on bCSCs. Therefore, active compounds need to be isolated from these extracts and tested at different time intervals. Even though there are many natural products available for cancer treatment, only a few compounds such as salinomycine, parthenolide, epigallocatechin gallate, curcumin, etc have successfully passed the in vitro studies for their efficacy in targeting CSCs. However clinical studies on these compounds have not yet been completed [10] . Therefore, the results of the present study can be used to search for novel anti-cancer compounds that can kill bCSCs.
CONCLUSION
The findings of the present study demonstrate that bark extracts of G. zeylanica, G. quaesita and S. castaneifolia inhibit the proliferation of bCSCs in vitro. This is the first study to report the anti-cancer activity of the selected Sri Lankan endemic plants (G. zeylanica, G. quaesita and S. castaneifolia) on breast cancer stem cells. Further studies are necessary to elucidate the mechanism of action of the anti-cancer stem cell activity of these plants and their isolated active compounds.
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